United States

People: Opexa Therapeutics Inc (OPXA.PH)

OPXA.PH on Philadelphia Stock Exchange

20 Jul 2016
Change (% chg)

-- (--)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Rill, Donna 

Ms. Donna R. Rill is Chief Development Officer of Opexa Therapeutics, Inc. Ms. Rill was appointed as our Chief Development Officer in April 2013 and previously served as Senior Vice President of Operations and Quality Systems since January 2009. From November 2004 until January 2009, she served as Vice President of Operations. From April 2003 to November 2004, she was the director of quality systems and process development at Opexa Pharmaceuticals, Inc. From November 1997 to April 2003, she was the director of translational research for the Center for Cell & Gene Therapy at Baylor College of Medicine. Ms. Rill has worked to design and qualify GMP Cell & Gene Therapy Laboratories, GMP Vector Production facilities, and Translational Research Labs at St. Jude Children’s Research Hospital, Texas Children’s Hospital, and Baylor College of Medicine. Ms. Rill received her B.S. in Medical Technology from the University of Tennessee, Memphis.

Basic Compensation

Total Annual Compensation, USD 318,109
Restricted Stock Awards, USD 22,500
Long-Term Incentive Plans, USD --
All Other, USD 232,417
Fiscal Year Total, USD 573,026

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --